Moderna (MRNA) reported $1.83 billion in revenue for the quarter ended September 2023, representing a year-over-year decline of 45.6%. EPS of -$1.39 for the same period compares to $2.53 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $1.33 billion, representing a surprise of +37.59%. The company delivered an EPS surprise of +30.85%, with the consensus EPS estimate being -$2.01.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company’s financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock’s price performance more accurately.
Here is how Moderna performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Product sales- United States: $913 million versus the two-analyst average estimate of $314.69 million.
- Product sales- Rest of world: $741 million compared to the $703.61 million average estimate based on two analysts.
- Product sales- Europe: $103 million versus $235.33 million estimated by two analysts on average.
- Revenue- Product sales: $1.76 billion versus $1.28 billion estimated by nine analysts on average. Compared to the year-ago quarter, this number represents a -43.7% change.
- Revenue- Other revenue: $74 million versus the six-analyst average estimate of $70.42 million.
- Revenue- Collaboration revenue: $30 million versus the four-analyst average estimate of $12.89 million. The reported number represents a year-over-year change of -70%.
- Revenue- Grant revenue: $44 million versus the three-analyst average estimate of $25.17 million. The reported number represents a year-over-year change of -69.4%.
View all Key Company Metrics for Moderna here>>>
Shares of Moderna have returned -30.8% over the past month versus the Zacks S&P 500 composite’s +0.8% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
4 Oil Stocks with Massive Upsides
Global demand for oil is through the roof… and oil producers are struggling to keep up. So even though oil prices are well off their recent highs, you can expect big profits from the companies that supply the world with “black gold.”
Zacks Investment Research has just released an urgent special report to help you bank on this trend.
In Oil Market on Fire, you’ll discover 4 unexpected oil and gas stocks positioned for big gains in the coming weeks and months. You don’t want to miss these recommendations.
Download your free report now to see them.
Moderna, Inc. (MRNA) : Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Image and article originally from www.nasdaq.com. Read the original article here.